Axcan Pharma Announces the Completion of its Canadian Multicentre Study for H. Pylori Eradication.MONTREAL--(BUSINESS WIRE)--Oct. 20, 1997--(ME, TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : AXP The brand name Digital gave to its first family of Alpha-based computers. In 1998, Digital was acquired by Compaq. See Alpha. .) Axcan Pharma Inc. announced that the efficacy analysis of its Canadian multicentre clinical study evaluating the co-administration of two antibiotics (tetracycline tetracycline (tĕ'trəsī`klēn), any of a group of antibiotics produced by bacteria of the genus Streptomyces. They are effective against a wide range of Gram positive and Gram negative bacteria, interfering with protein , metronidazole metronidazole /met·ro·ni·da·zole/ (-ni´dah-zol) an antiprotozoal and antibacterial effective against obligate anaerobes; used as the base or the hydrochloride salt. It is also used as a topical treatment for rosacea. ) and Axcan's Barrier" product (colloidal colloidal of the nature of a colloid. colloidal bath a bath containing gelatin, bran, starch or similar substances, to relieve skin irritation and pruritus. bismuth subcitrate) in eradicating Helicobacter pylori (H. pylori) bacteria is now completed with extremely encouraging results. This double blind placebo controlled phase III study involved research centres in Halifax, Montreal, Vancouver, Toronto, Hamilton and Edmonton. The study involved ulcer and dyspepsia dyspepsia: see indigestion. patients. The final results from the study will be submitted for presentation at the Canadian Digestive Diseases Week in March 1998. "We are very pleased that this study is now completed and we are even happier with the results including the high intent-to-treat Hp eradication rates obtained as well as the high percentage of patients who completed the study," said Leon Gosselin, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Axcan Pharma Inc. "We are now working on a New Drug Submission which should be filed with the Canadian HPB HPB Health Promotion Board (Singapore) HPB Hrvatska Poštanska Banka (Croatian Post Bank) HPB Half Price Books (retail store) HPB High Ping Bastard early in calendar 1998," he added. For several years now it has been accepted that H. pylori is the main cause of chronic gastritis, and both gastric and duodenal ulcers. Left untreated, the H. Epylori bacteria can live in the stomach for years or even a lifetime. Often people who are infected don't have any symptoms or any serious problems. About 15 percent of people infected with H. pylori will develop an ulcer in their lifetime. Even if an ulcer is cured with traditional anti- ulcer medication, there is an 80 percent risk of recurrence after one year if the infection is not completely eradicated. Following successful eradication therapy, the recurrence rate is less than 5 percent within a year thus eliminating costly maintenance medications ($500 to $1,000 yearly per patient). Axcan Pharma is a Canadian pharmaceutical company involved in the development and distribution of pharmaceutical products, mainly in the field of gastroenterology. The Company has nearly 100 employees at its head office in Mont St-Hilaire and its laboratory in Laval (Quebec). Axcan is one of the ten largest publicly traded health-care companies in Canada and is listed on the Montreal and Toronto Stock Exchanges under the symbol AXP. CONTACT: Axcan Pharma Inc. Bertrand Bolduc, 514/467-5138 514/464-9979 (FAX) bbolduc@axcan.com http://www.axcan.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion